Difference between revisions of "Samarium-153 (Quadramet)"
m |
|||
| Line 12: | Line 12: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 3/28/1997: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 21: | Line 24: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Radioactive agents]] | [[Category:Radioactive agents]] | ||
| − | [[Category:Prostate cancer medications]] | + | |
| + | [[Category:Bone cancer medications]] [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1997]] | ||
Revision as of 22:55, 4 November 2014
General information
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 3/28/1997: Initial FDA approval
Also known as
153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, 152Sm2O3.